HealthCare Global Enterprises Limited (HCG), South Asia’s largest cancer care network, has moved on to offer accurate assessment of blood flow into the heart with its latest on-site availability of medical cyclotron and high end mCT (molecular CT).
The 128 slice PET-CT is now embedded with a cardiac software applications like MBF quantification. This will help the clinicians to provide a non-invasive method to determine myocardial blood flow and accurately assess the need for revascularization procedures such as stenting and bypass surgery.
With this HCG has reiterated its commitment to bring cutting edge technology and enable its consultants to offer timely & precise diagnosis and manage disorders. HCG is the only hospital in the whole of Asia to have this kind of facility offering MBF, according to Dr Ajaikumar, chairman, HCG.
The commissioning of MBF opens an exciting new dimension in quantitative metabolic imaging and also marks its foray into cardiology diagnosis. The MBF provides an absolute measure for blood flow in the myocardium to assess perfusion that hitherto remained undetected with conventional relative perfusion imaging. This standard single procedure is also fast that takes no longer than 30 minutes and is a very safe OPD procedure.
Dr Ajaikumar said, “We have a vision to be at the forefront of technology and introduce revolutionary diagnostic and treatment equipment at our centres. This launch is yet another milestone as we step beyond oncology and foray into cardiology diagnosis. With diabetic incidence increasing exponentially in India the risk of micro vascular disease amongst this group is particularly high and MBF System is the only way to ascertain the hearts health.”
Dr K G Kallur, director, Molecular Imaging, HCG said, “We are the first centre in Asia to offer quantification of MBF for a Cardiologist, which is also called as FFR (Fractional Flow Reserve). At present FFR is done by only few cardiologists in India and it is invasive. At HCG, MBF test is absolutely non-invasive and safe. MBF test is expected to become a Gold Standard in evaluating the need for re-vascularisation procedures such as angioplasty, stenting and CABG in indeterminate blocks in the coronary arteries.”